Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2015

At a glance

  • Drugs SOBI 002 (Primary) ; SOBI 002 (Primary)
  • Indications Autoimmune disorders; Inflammation
  • Focus Adverse reactions
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 27 Jul 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 09 Nov 2014 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov.
    • 24 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top